Literature DB >> 31196854

Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?

Richard T Piszczatowski1, Ulrich Steidl2,3,4,5.   

Abstract

The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.See related article by Gangat et al., p. 4898. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31196854      PMCID： PMC6697558          DOI： 10.1158/1078-0432.CCR-19-1481

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

Authors:  Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 3.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

Authors:  Laure Gilles; Ahmet Dirim Arslan; Christian Marinaccio; Qiang Jeremy Wen; Priyanka Arya; Maureen McNulty; Qiong Yang; Jonathan C Zhao; Katerina Konstantinoff; Terra Lasho; Animesh Pardanani; Brady Stein; Isabelle Plo; Sriram Sundaravel; Amittha Wickrema; Annarita Migliaccio; Sandeep Gurbuxani; William Vainchenker; Leonidas C Platanias; Ayalew Tefferi; John D Crispino
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

7.  Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Authors:  Qiang Wen; Benjamin Goldenson; Serena J Silver; Monica Schenone; Vlado Dancik; Zan Huang; Ling-Zhi Wang; Timothy A Lewis; W Frank An; Xiaoyu Li; Mark-Anthony Bray; Clarisse Thiollier; Lauren Diebold; Laure Gilles; Martha S Vokes; Christopher B Moore; Meghan Bliss-Moreau; Lynn Verplank; Nicola J Tolliday; Rama Mishra; Sasidhar Vemula; Jianjian Shi; Lei Wei; Reuben Kapur; Cécile K Lopez; Bastien Gerby; Paola Ballerini; Francoise Pflumio; D Gary Gilliland; Liat Goldberg; Yehudit Birger; Shai Izraeli; Alan S Gamis; Franklin O Smith; William G Woods; Jeffrey Taub; Christina A Scherer; James E Bradner; Boon-Cher Goh; Thomas Mercher; Anne E Carpenter; Robert J Gould; Paul A Clemons; Steven A Carr; David E Root; Stuart L Schreiber; Andrew M Stern; John D Crispino
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

8.  Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.

Authors:  Naseema Gangat; Christian Marinaccio; Ronan Swords; Justin M Watts; Sandeep Gurbuxani; Alfred Rademaker; Angela J Fought; Olga Frankfurt; Jessica K Altman; Qiang Jeremy Wen; Noushin Farnoud; Christopher A Famulare; Akshar Patel; Roberto Tapia; Rangit R Vallapureddy; Stephanie Barath; Amy Graf; Amy Handlogten; Darci Zblewski; Mrinal M Patnaik; Aref Al-Kali; Yvonne Trang Dinh; Kristen Englund Prahl; Shradha Patel; Juan Carlos Nobrega; Dalissa Tejera; Amber Thomassen; Juehua Gao; Peng Ji; Raajit K Rampal; Francis J Giles; Ayalew Tefferi; Brady Stein; John D Crispino
Journal:  Clin Cancer Res       Date:  2019-05-06       Impact factor: 12.531

9.  Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Authors:  Qiang Jeremy Wen; Qiong Yang; Benjamin Goldenson; Sébastien Malinge; Terra Lasho; Rebekka K Schneider; Lawrence J Breyfogle; Rachael Schultz; Laure Gilles; Priya Koppikar; Omar Abdel-Wahab; Animesh Pardanani; Brady Stein; Sandeep Gurbuxani; Ann Mullally; Ross L Levine; Ayalew Tefferi; John D Crispino
Journal:  Nat Med       Date:  2015-11-16       Impact factor: 53.440

10.  Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Authors:  C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528
  10 in total
  2 in total

Review 1.  Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors:  Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

Review 2.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.